- Home
- RDY vs ADPT Comparison
RDY vs ADPT Comparison
Compare RDY & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDY
- ADPT
- Stock Information
- Founded
- RDY 1984
- ADPT 2009
- Country
- RDY India
- ADPT United States
- Employees
- RDY N/A
- ADPT N/A
- Industry
- RDY Biotechnology: Pharmaceutical Preparations
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDY Health Care
- ADPT Health Care
- Exchange
- RDY Nasdaq
- ADPT Nasdaq
- Market Cap
- RDY 2.1B
- ADPT 1.8B
- IPO Year
- RDY N/A
- ADPT 2019
- Fundamental
- Price
- RDY $14.53
- ADPT $11.82
- Analyst Decision
- RDY Strong Buy
- ADPT Strong Buy
- Analyst Count
- RDY 2
- ADPT 7
- Target Price
- RDY $16.95
- ADPT $10.57
- AVG Volume (30 Days)
- RDY 1.5M
- ADPT 2.4M
- Earning Date
- RDY 07-28-2025
- ADPT 07-31-2025
- Dividend Yield
- RDY 0.56%
- ADPT N/A
- EPS Growth
- RDY 1.47
- ADPT N/A
- EPS
- RDY 0.79
- ADPT N/A
- Revenue
- RDY $3,809,801,863.00
- ADPT $189,527,000.00
- Revenue This Year
- RDY $10.24
- ADPT $24.46
- Revenue Next Year
- RDY N/A
- ADPT $20.25
- P/E Ratio
- RDY $18.39
- ADPT N/A
- Revenue Growth
- RDY 16.61
- ADPT 8.61
- 52 Week Low
- RDY $12.26
- ADPT $3.51
- 52 Week High
- RDY $16.89
- ADPT $12.43
- Technical
- Relative Strength Index (RSI)
- RDY 37.98
- ADPT 63.35
- Support Level
- RDY $14.81
- ADPT $11.41
- Resistance Level
- RDY $15.25
- ADPT $12.36
- Average True Range (ATR)
- RDY 0.20
- ADPT 0.59
- MACD
- RDY -0.12
- ADPT -0.01
- Stochastic Oscillator
- RDY 5.18
- ADPT 72.65
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).